Publication | Closed Access
Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer
60
Citations
0
References
2021
Year
MedicineCancer ManagementGynecologyRecurrent Ovarian CancerSecondary Efficacy EndpointsLong-term SafetyCancer TreatmentOncologyRadiation OncologyGynecology OncologyOvarian Cancer
No additional data available for this publication yet. Check back later!